{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:15:15Z","timestamp":1783026915262,"version":"3.54.6"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Nucleotide analogues may promote renal and bone toxicity. The aim of the present study was to evaluate markers of osteorenal toxicity in patients affected by hepatitis B virus-related chronic hepatitis treated with lamivudine plus adefovir who were switched to tenofovir.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>We evaluated 60 consecutive patients at the time of the switch of treatment and after 1, 3, 6, 9 and 12 months. The mean baseline estimated glomerular filtration rate (eGFR) was 89.3\u200a\u00b1\u200a19.0 mL\/min\/1.73 m2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the study period we observed a reduction in mean eGFR up to 6 months after switching to tenofovir, and this remained stable for the last two timepoints. At the end of study, the mean eGFR was 82.6\u200a\u00b1\u200a21.5 mL\/min\/1.73 m2, a reduction of 7.5%. The mean baseline proteinuria was 202.6\u200a\u00b1\u200a237.6 mg\/24 h. Microhaematuria was observed in 22.6% of patients and hypophosphataemia in 18.6%. After 1 month of tenofovir, we observed a worsening of serum phosphate and parathyroid hormone levels, haemoglobinuria and 24 h proteinuria. After 3 and 12 months of tenofovir, these data tended to recover to baseline levels. A total of 92.6% of patients at baseline had hypovitaminosis D. After supplementation with cholecalciferol, this percentage decreased significantly. We observed a reduced bone mineral density (BMD) in 52.7% of patients at baseline; this increased to 77.8% after 6 months of tenofovir, but at the last timepoint the percentage of patients with a reduced BMD had fallen to a level above the baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In conclusion, patients exposed to lamivudine plus adefovir showed relevant osteorenal damage. The switch to tenofovir provoked a slight reduction in eGFR that stabilized after 6 months. The reduced BMD at baseline did not worsen under tenofovir treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dku502","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T10:58:42Z","timestamp":1418986722000},"page":"1150-1154","source":"Crossref","is-referenced-by-count":46,"title":["Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study"],"prefix":"10.1093","volume":"70","author":[{"given":"Paolo","family":"Maggi","sequence":"first","affiliation":[{"name":"1 \u00a0Institute of Infectious Diseases, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Montinaro","sequence":"additional","affiliation":[{"name":"2 \u00a0Institute of Nephrology, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Leone","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Infectious Diseases, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Fasano","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Infectious Diseases, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Volpe","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Infectious Diseases, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bellacosa","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Infectious Diseases, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Grattagliano","sequence":"additional","affiliation":[{"name":"3 \u00a0Institute of Rheumatology, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Coladonato","sequence":"additional","affiliation":[{"name":"3 \u00a0Institute of Rheumatology, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[{"name":"3 \u00a0Institute of Rheumatology, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Santantonio","sequence":"additional","affiliation":[{"name":"4 \u00a0Institute of Infectious Diseases, Policlinico-University of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"Angarano","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Infectious Diseases, Policlinico-University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"key":"2022020120582712900_DKU502C1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14740338.2011.593507","article-title":"Drug safety evaluation of adefovir in HBV infection","volume":"10","author":"Vigan\u00f2","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"2022020120582712900_DKU502C2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2009.142","article-title":"The nephrotoxic effects of HAART","volume":"5","author":"Izzedine","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2022020120582712900_DKU502C3","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1128\/AAC.00251-06","article-title":"Mechanism of active renal tubular efflux of tenofovir","volume":"50","author":"Ray","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120582712900_DKU502C4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-na\u00efve patients: a randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"2022020120582712900_DKU502C5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DT, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"2022020120582712900_DKU502C6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-na\u00efve HIV-1-infected patients at 48 weeks","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"2022020120582712900_DKU502C7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/aid.2007.0107","article-title":"A lopinavir\/ritonavir based once-daily regimen results in better compliance and is noninferior to a twice-daily regimen through 96 weeks","volume":"23","author":"Molina","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022020120582712900_DKU502C8","first-page":"122","article-title":"Renal dysfunction and tenofovir toxicity in HIV-infected patients","volume":"16","author":"Szczech","year":"2008","journal-title":"Top HIV Med"},{"key":"2022020120582712900_DKU502C9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2009.08.006","article-title":"HIV and CKD epidemiology","volume":"17","author":"Winston","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"2022020120582712900_DKU502C10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1523-1755.2005.00229.x","article-title":"The clinical characteristics of HIV-infected patients receiving dialysis in France between 1997 and 2002","volume":"67","author":"Vigneau","year":"2005","journal-title":"Kidney Int"},{"key":"2022020120582712900_DKU502C11","first-page":"649A","article-title":"Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance","volume":"4","author":"Marcellin","year":"2013","journal-title":"Hepatology"},{"key":"2022020120582712900_DKU502C12","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.dld.2014.01.109","article-title":"High rates of tenofovir dose adjustments are required in adefovir experienced patients with chronic hepatitis B: a 4-years prospective study in 320 patients","volume":"46","author":"Lampertico","year":"2014","journal-title":"Dig Liver Dis"},{"key":"2022020120582712900_DKU502C13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022020120582712900_DKU502C14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/106002809402800513","article-title":"Drug- and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill","volume":"28","author":"Brown","year":"1994","journal-title":"Ann Pharmacother"},{"key":"2022020120582712900_DKU502C15","volume-title":"Proceedings of the American Society of Nephrology","author":"Thomas","year":"2006"},{"key":"2022020120582712900_DKU502C16","first-page":"179","article-title":"Studio epidemiologico delle malattie renali nella provincia di Siena: risultati dello screening di massa","volume-title":"Epidemiologia delle malattie renali.","author":"Di Paolo","year":"1991"},{"key":"2022020120582712900_DKU502C17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s001980050141","article-title":"High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening","volume":"9","author":"Bettica","year":"1999","journal-title":"Osteoporos Int"},{"key":"2022020120582712900_DKU502C18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/QAI.0b013e3181be6be2","article-title":"Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients","volume":"53","author":"Horberg","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022020120582712900_DKU502C19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jgh.12499","article-title":"Extra-hepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment","volume":"29","author":"Fung","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"2022020120582712900_DKU502C20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1468-1293.2006.00407.x","article-title":"Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy","volume":"7","author":"Buchacz","year":"2006","journal-title":"HIV Med"},{"key":"2022020120582712900_DKU502C21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/aid.2011.0052","article-title":"Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir","volume":"28","author":"Masi\u00e1","year":"2012","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/4\/1150\/42355875\/jac_70_4_1150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/4\/1150\/42355875\/jac_70_4_1150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T21:03:36Z","timestamp":1643749416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/4\/1150\/802597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,12,18]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku502","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,4]]},"published":{"date-parts":[[2014,12,18]]}}}